An open-label extension study of XPro1595 in patients with Alzheimer's Disease

Inmune Bio, Inc is starting a new clinical trial of An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease.

The goal of this Phase 2 Open-Label Extension (OLE) is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with mild Alzheimer's Disease or MCI with biomarkers of inflammation.

This study targets patients with mild Alzheimer's Disease (AD). Participants who received the drug during this study, and subsequently join the OLE study, will be on XPro1595 for an additional 12 months (52 weeks). Their total exposure to XPro1595 will be up to 18 months (76 weeks). 

The clinical trial starts in November 2022 and will continue throughout December 4, 2025.

For more details: https://ichgcp.net/clinical-trials-registry/NCT05522387.